Carlos de la Rosa-Baez

Mr. Carlos de la Rosa-Baez

Biología Celular e Inmunología, Institute of Parasitology and Biomedicine "López-Neyra", Granada, Andalusia, Spain
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2023 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
EHEsther Herrera-Luis
Esther Herrera-Luis
Carlos de la Rosa-BaezCarlos de la Rosa-Baez
Carlos de la Rosa-Baez
SHScott Huntsman
Scott Huntsman
CECeleste Eng
Celeste Eng
KBKenneth B. Beckman
Kenneth B. Beckman
Maria Pino-YanesMaria Pino-Yanes
Maria Pino-Yanes
Background: The epigenetic mechanisms of asthma remain largely understudied in African Americans and Hispanics/Latinos, two populations disproportionately affected by asthma. We aimed to identify markers, regions and processes with differential patterns of DNA methylation (DNAm) in whole blood by asthma status in ethnically diverse children and youth, and to assess their functional consequences.Methods: DNAm levels were profiled with the Infinium MethylationEPIC or HumanMethylation450 BeadChip arrays among 1226 African Americans or Hispanics/Latinos and assessed for differential methylation per asthma status at the CpG and region (differentially methylated region (DMR)) level. Novel associations were validated in blood and/or nasal epithelium from ethnically diverse children and youth. The functional and biological implications of the markers identified were investigated by combining epigenomics with transcriptomics from study participants.Results: 128 CpGs and 196 DMRs were differentially methylated after multiple testing corrections, including 92.3% and 92.8% novel associations, respectively. 41 CpGs were replicated in other Hispanics/Latinos, prioritising cg17647904 (NCOR2) and cg16412914 (AXIN1) as asthma DNAm markers. Significant DNAm markers were enriched in previous associations for asthma, fractional exhaled nitric oxide, bacterial infections, immune regulation or eosinophilia. Functional annotation highlighted epigenetically regulated gene networks involved in corticosteroid response, host defence and immune regulation. Several implicated genes are targets for approved or experimental drugs, includingTNNC1andNDUFA12. Many differentially methylated loci previously associated with asthma were validated in our study.Conclusions: We report novel whole-blood DNAm markers for asthma underlying key processes of the disease pathophysiology and confirm the transferability of previous asthma DNAm associations to ethnically diverse populations.

23 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Mario Martín AlmeidaMario Martín Almeida
Mario Martín Almeida
JPJavier Perez-Garcia
Javier Perez-Garcia
EHEsther Herrera-Luis
Esther Herrera-Luis
Carlos de la Rosa-BaezCarlos de la Rosa-Baez
Carlos de la Rosa-Baez
MGMario Gorenjak
Mario Gorenjak
OCon behalf of the SysPharmPediA Consortium
on behalf of the SysPharmPediA Consortium
Asthma is the most prevalent pediatric chronic disease. Bronchodilator drug response (BDR) and fractional exhaled nitric oxide (FeNO) are clinical biomarkers of asthma. Although DNA methylation (DNAm) contributes to asthma pathogenesis, the influence of DNAm on BDR and FeNO is scarcely investigated. This study aims to identify DNAm markers in whole blood associated either with BDR or FeNO in pediatric asthma. We analyzed 121 samples from children with moderate-to-severe asthma. The association of genome-wide DNAm with BDR and FeNO has been assessed using regression models, adjusting for age, sex, ancestry, and tissue heterogeneity. Cross-tissue validation was assessed in 50 nasal samples. Differentially methylated regions (DMRs) and enrichment in traits and biological pathways were assessed. A false discovery rate (FDR) < 0.1 and a genome-wide significance threshold of p < 9 × 10−8 were used to control for false-positive results. The CpG cg12835256 (PLA2G12A) was genome-wide associated with FeNO in blood samples (coefficient= −0.015, p = 2.53 × 10−9) and nominally associated in nasal samples (coefficient = −0.015, p = 0.045). Additionally, three CpGs were suggestively associated with BDR (FDR < 0.1). We identified 12 and four DMRs associated with FeNO and BDR (FDR < 0.05), respectively. An enrichment in allergic and inflammatory processes, smoking, and aging was observed. We reported novel associations of DNAm markers associated with BDR and FeNO enriched in asthma-related processes.

1 July 2025 in RMD Open
Verified
Journal Article
Open access
Carlos de la Rosa-BaezCarlos de la Rosa-Baez
Carlos de la Rosa-Baez
CRCarlos Rangel-Pelaez
Carlos Rangel-Pelaez
IRInmaculada Rodriguez-Martin
Inmaculada Rodriguez-Martin
MKMartin Kerick
Martin Kerick
AGAlfredo Guillen-Del-Castillo
Alfredo Guillen-Del-Castillo
IGInternational SSc Group
International SSc Group
Objective: The common gain-of-function variant rs35705950, located in the promoter of MUC5B gene, has been strongly associated with interstitial lung diseases (ILDs) of different aetiology, such as idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis-associated ILD (RA-ILD). In this study, we aimed to investigate the association of this variant and its nearby single nucleotide polymorphisms (SNPs) in the largest cohort of systemic sclerosis-associated ILD (SSc-ILD) to date. Methods: Samples were collected from blood/saliva, followed by DNA extraction and genotyping using SNP arrays. Data for rs35705950 and additional 903 variants within 100 Kb were obtained using genomic imputation. Subsequently, we tested their association in a meta-analysis to increase the consistency of the results, including 10 European ancestry cohorts comprising 2363 patients with SSc-ILD, 3526 SSc patients without ILD and 15 076 controls. Results: Meta-analysis showed no significant association between rs35705950 and SSc-ILD, either comparing patients with SSc with and without ILD (p value: 0.588, OR: 1.05, 95% CI: 0.87 to 1.27) nor patients with SSc-ILD with controls (p value: 0.061, OR: 1.16, 95% CI: 0.99 to 1.36). Moreover, none of the additional 903 variants tested in the genomic region reached statistical significance. Conclusion: Despite analysing the largest and most statistically powered SSc-ILD cohort to date, we found no evidence of association between the MUC5B promoter variant rs35705950 and its surrounding SNPs with SSc-ILD. These results suggest that the pathogenic mechanisms underlying SSc-ILD may only partially overlap with those of other similar ILDs, such as IPF or RA-ILD. This highlights the need for further studies regarding their genetic architecture.

29 January 2025 in Rheumatology
Verified
Journal Article
Open access
Carlos de la Rosa-BaezCarlos de la Rosa-Baez
Carlos de la Rosa-Baez
GBGonzalo Borrego-Yaniz
Gonzalo Borrego-Yaniz
IRInmaculada Rodriguez-Martin
Inmaculada Rodriguez-Martin
MKMartin Kerick
Martin Kerick
MAMarialbert Acosta-Herrera
Marialbert Acosta-Herrera
LOLourdes Ortiz-Fernández
Lourdes Ortiz-Fernández
Objectives: Coronavirus disease 2019 (COVID-19) and SSc share multiple similarities in their clinical manifestations, alterations in immune response and therapeutic options. These resemblances have also been identified in other immune-mediated inflammatory diseases where a common genetic component has been found. Thus, we decided to evaluate for the first time this shared genetic architecture with SSc. Methods: For this study, we retrieved genomic data from two European-ancestry cohorts: 2 597 856 individuals from The COVID-19 Host Genetics Initiative consortium, and 26 679 individuals from the largest genomic scan in SSc. We performed a cross-trait meta-analyses including >9.3 million single nucleotide polymorphisms. Finally, we conducted functional annotation to prioritize potential causal genes and performed drug repurposing analysis. Results: Our results revealed a total of 19 non-HLA pleiotropic loci, including 2 novel associations for both conditions (BMP1 and PPARG) and 12 emerging as new shared loci. Functional annotation of these regions underscored their potential regulatory role and identified potential causal genes, many of which are implicated in fibrotic and inflammatory pathways. Remarkably, we observed an antagonistic pleiotropy model of the IFN signalling between COVID-19 and SSc, including the well-known TYK2 P1104A missense variant, showing a protective effect for SSc while being a risk factor for COVID-19, along with two additional novel pleiotropic associations (IRF8 and SENP7). Finally, our findings provide new therapeutic options that could potentially benefit both conditions. Conclusion: Our study confirms the genetic resemblance between susceptibility to and severity of COVID-19 and SSc, revealing a novel common genetic contribution affecting fibrotic and immune pathways.

8 April 2026 in Rheumatology
Verified
Journal Article
Open access
CRCarlos Rangel-Peláez
Carlos Rangel-Peláez
IRInmaculada Rodriguez-Martin
Inmaculada Rodriguez-Martin
Carlos de la Rosa-BaezCarlos de la Rosa-Baez
Carlos de la Rosa-Baez
MKMartin Kerick
Martin Kerick
AGAlfredo Guillen-Del-Castillo
Alfredo Guillen-Del-Castillo
I(International SSc Group, the PRECISESADS Clinical Consortium, and the Australian Scleroderma Interest Group (ASIG)
International SSc Group, the PRECISESADS Clinical Consortium, and the Australian Scleroderma Interest Group (ASIG)
Objective: Raynaud’s phenomenon (RP) is the first noticeable symptom of systemic sclerosis (SSc), appearing even years before other signs. Vascular and immune pathways, hallmarks in SSc pathogenesis, are implicated in primary RP. Hence, we aimed to define the shared genetic architecture between these conditions to explore pathogenic mechanisms and whether pleiotropic loci could help identify primary RP patients at increased genetic risk of developing SSc. Methods: We analysed genome-wide association study (GWAS) summary statistics for primary RP (4 986 cases and 850 981 controls) and SSc (10 654 cases and 18 043 controls). We performed a cross-trait meta-analysis (∼8.6M single nucleotide polymorphisms) to identify variants associated with both diseases. Functional annotation was used to prioritise potential causal genes. We also constructed a polygenic risk score (PRS) to assess clinical implications. Results: Beyond the well-known HLA associations, we identified five additional pleiotropic loci, including MEOX2 as a novel association for both traits with opposing effects, ADRA2A representing a novel genetic factor for SSc, and IL12A, NFKB1 and TNIP1 as novel loci for primary RP. Functional annotation highlighted vascular and inflammatory pathways. Finally, the PRS model shows modest discrimination (area under the curve = 0.57). However, it allows the identification of primary RP individuals at high genetic risk of developing SSc (75th percentile, relative risk =1.29 [95% CI 1.02, 1.62]; P-value= 3.58 × 10−2). Conclusion: This study reveals a genetic link between primary RP and SSc, identifying five novel pleiotropic loci and supporting the potential of genetic profiling for early risk assessment and personalised monitoring strategies.

30 May 2026 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
Carlos de la Rosa-BaezCarlos de la Rosa-Baez
Carlos de la Rosa-Baez
CRCarlos Rangel-Peláez
Carlos Rangel-Peláez
IRInmaculada Rodriguez-Martin
Inmaculada Rodriguez-Martin
GBGonzalo Borrego-Yaniz
Gonzalo Borrego-Yaniz
MKMartin Kerick
Martin Kerick
MAMarialbert Acosta-Herrera
Marialbert Acosta-Herrera